{
    "organizations": [],
    "uuid": "c8bdff5bd5c13aa8cad5ae444ceee55cbbdb86e2",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/03/06/globe-newswire-cymabay-to-report-fourth-quarter-and-fiscal-year-2017-financial-results-on-thursday-march-15.html",
    "ord_in_thread": 0,
    "title": "CymaBay to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 15",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "NEWARK, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, March 15, 2018 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2017 and to provide a business update.\nConference Call Details\nTo access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13676717. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events .\nAbout CymaBay\nCymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof of concept in PBC. CymaBay is currently planning to advance development of seladelpar into Phase 3 for PBC and Phase 2 for NASH.\nFor additional information about CymaBay visit www.cymabay.com .\nContact:\nHans Vitzthum\nLifeSci Advisors, LLC\n212-915-2568\nHans@LifeSciAdvisors.com\nSource:CymaBay Therapeutics, Inc.",
    "published": "2018-03-06T16:00:00.000+02:00",
    "crawled": "2018-03-06T18:19:01.062+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "newark",
        "march",
        "globe",
        "newswire",
        "cymabay",
        "therapeutic",
        "nasdaq",
        "cbay",
        "biopharmaceutical",
        "company",
        "focused",
        "developing",
        "therapy",
        "liver",
        "chronic",
        "disease",
        "high",
        "unmet",
        "need",
        "today",
        "announced",
        "host",
        "conference",
        "call",
        "live",
        "audio",
        "webcast",
        "thursday",
        "march",
        "eastern",
        "time",
        "discus",
        "financial",
        "result",
        "fourth",
        "quarter",
        "year",
        "ended",
        "december",
        "provide",
        "business",
        "update",
        "conference",
        "call",
        "detail",
        "access",
        "live",
        "conference",
        "call",
        "please",
        "dial",
        "canada",
        "internationally",
        "conference",
        "id",
        "access",
        "live",
        "subsequently",
        "archived",
        "webcast",
        "conference",
        "call",
        "go",
        "investor",
        "section",
        "company",
        "website",
        "http",
        "cymabay",
        "cymabay",
        "therapeutic",
        "cbay",
        "biopharmaceutical",
        "company",
        "focused",
        "developing",
        "therapy",
        "liver",
        "chronic",
        "disease",
        "high",
        "unmet",
        "medical",
        "need",
        "seladelpar",
        "potent",
        "selective",
        "orally",
        "active",
        "pparδ",
        "agonist",
        "currently",
        "development",
        "treatment",
        "patient",
        "primary",
        "biliary",
        "cholangitis",
        "pbc",
        "autoimmune",
        "liver",
        "disease",
        "nonalcoholic",
        "steatohepatitis",
        "nash",
        "two",
        "phase",
        "study",
        "seladelpar",
        "established",
        "proof",
        "concept",
        "pbc",
        "cymabay",
        "currently",
        "planning",
        "advance",
        "development",
        "seladelpar",
        "phase",
        "pbc",
        "phase",
        "nash",
        "additional",
        "information",
        "cymabay",
        "visit",
        "contact",
        "han",
        "vitzthum",
        "lifesci",
        "advisor",
        "llc",
        "han",
        "source",
        "cymabay",
        "therapeutic",
        "inc"
    ]
}